Clinical trials: Neoplasms, Metastatic
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic
NR in Chemo-induced Peripheral Neuropathy
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV
- Trial name
- NCT03642990
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Donna Hammond, PhD
Castration-resistant Prostate Cancer
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is…
- Trial name
- PERSEUS1 (NCT03506997)
- Testing
- Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Institute of Cancer Research, United Kingdom
HER2 Amplified, Advanced Breast Cancer
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.
- Conditions
- HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
- Trial name
- NCT02091960
- Testing
- Enzalutamide, Trastuzumab
- Where
- 39 sites in United States, Belgium and 4 more
- Volunteers
- 103 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Malignant Solid Tumour
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.
- Trial name
- NCT02857920
- Testing
- Bevacizumab, NK immunotherapy
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C…
- Trial name
- NCT06435455
- Testing
- GH21, D-1553
- Volunteers
- 126 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Metastatic Colorectal Cancer
"Cancersensor": Circadian Rhythms
Observational, non randomized study aimed at measuring the circadian rhythms in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer and in 30 age and sex-matched…
- Trial name
- NCT01693835
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Prostate Cancer
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubular network agent and is one of the most active agents in the treatment of…
- Trial name
- NCT01188408
- Testing
- Liposome Entrapped Docetaxel (LE-DT)
- Where
- 2 sites in United States
- Sponsor
- INSYS Therapeutics Inc
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical
Metastatic Colorectal Cancer
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.
- Trial name
- SIRB2 (NCT03380689)
- Testing
- S-1, Irinotecan, Bevacizumab
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Neoplasm Metastasis, Colorectal Neoplasms
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer…
- Conditions
- Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
- Trial name
- NCT02124148
- Testing
- Prexasertib, Cisplatin, Cetuximab
- Where
- 5 sites in United States
- Volunteers
- 167 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial
The purpose of this study is to evaluate the efficacy and safety of vinorelbine plus oxaliplatin in pretreated metastatic triple-negative breast cancer.
- Trial name
- NVBOX (NCT01528826)
- Testing
- vinorelbine plus oxaliplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fudan University
Pancreatic Cancer
Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
The purpose of this study is to compare the overall survival in patients with previously untreated metastatic pancreatic cancer receiving gemcitabine/nab-paclitaxel plus OGX-427 or gemcitabine/nab-paclitaxel plus placebo.
- Trial name
- Rainier (NCT01844817)
- Testing
- OGX-427
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- SCRI Development Innovations, LLC
Esophageal Squamous Cell Carcinoma
Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
This phase Ⅱ study was designed to evaluate the efficacy and safety of endostar combined with paclitaxel and nedaplatin as first-line therapy in treating patients with recurrent or metastatic esophageal squamous cell cancer.
- Trial name
- NCT02350517
- Testing
- Paclitaxel+Nedaplatin+Endostar
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Yuhong Li
Bladder Cancer, Cervical Cancer
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer.
- Conditions
- Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01087268
- Testing
- questionnaire administration, gastrointestinal complications management/prevention, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Breast Cancer
Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer
- Trial name
- NCT00524810
- Testing
- Pegylated liposomal doxorubicin, Docetaxel
- Where
- France
- Volunteers
- 67 people
- Sponsor
- ARCAGY/ GINECO GROUP
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma
- Trial name
- NCT05098210
- Testing
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer Metastatic, Breast Cancer Brain Metastases
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
In phase Ib, our study is aimed to evaluate the safety and tolerance of SHR-A1811 combined with pyrotinib in breast cancer with brain metastasis, and confirm the recommended phase 2 dose combined with preliminary results of…
- Trial name
- NCT06718933
- Testing
- SHR-A1811, Bevacizumab, Pyrotinib
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
This pilot phase I trial studies the side effects and best dose of CPI-613 when given together with fluorouracil in treating patients with colorectal cancer that has spread to other parts of the body and cannot be removed by…
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT02232152
- Testing
- 6,8-bis(benzylthio)octanoic acid, fluorouracil, pharmacological study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Renal Cell Carcinoma
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial…
- Trial name
- NCT06770855
- Testing
- Total consolidative MPDT
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer Stage IV
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
This is an open-label, single arm, non-randomized, multicenter, phase 2 study assessing the efficacy and safety of T-DXd as first-line treatment in HER2-positive advanced/metastatic BC patients (N=300).
- Trial name
- TOP-REAL (NCT07371585)
- Testing
- Digital Health Tools, T-DXd, Pertuzumab
- Where
- 27 sites in France, Germany and 1 more
- Volunteers
- 300 people
- Sponsor
- SOLTI Breast Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.